European Equities Traded in the US as American Depositary Receipts Drop in Thursday Trading

MT Newswires Live09-10 23:34

European equities traded in the US as American depositary receipts were trending lower late Thursday morning, declining 0.41% to 1,938.57 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and accommodations booking site trivago (TRVG), which advanced 1.6% and 1.1% respectively. They were followed by medical device maker EDAP TMS (FOCL) and 3D printer company Materialise (MTLS), which increased 1.2% and 0.8% respectively.

The decliners from continental Europe were led by biotech firm Evaxion (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which lost 5% and 2.7% respectively. They were followed by biotech firm BioNTech (BNTX) and biopharmaceutical company Grifols (GRFS), which were down 1.8% and 1.7% respectively.

The gainers from the UK were led by software firm Endava (DAVA) and biopharmaceutical company Akari Therapeutics (AKTX), which were up 2% and 1.6% respectively. They were followed by telecommunications operator Vodafone Group (VOD) and pharmaceutical company AstraZeneca (AZN), which rose 1.2% and 1.5% respectively.

The decliners from the UK and Ireland were led by mining company BHP Group (BHP) and biotech firm Trinity Biotech (TRIB), which fell 4.7% and 5.6% respectively. They were followed by biopharmaceutical companies Amarin (AMRN) and Biodexa Pharmaceuticals (BDRX), which dropped 2.2% and 3% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment